Use of n-3 PUFAs can decrease the mortality in patients with systemic inflammatory response syndrome: a systematic review and meta-analysis

Table 2 Meta-analysis of included trials

Outcome of interest	No. of trials	No. of patients	Fixed effect model			Random effects model
Outcome of interest	No. of trials	No. of patients	RR/WMD (95% CI)	P	I²	RR/WMD (95% CI)	P	I²
Mortality	8	706	0.77 [0.60, 0.97]	0.03	0%	-	-	-
Days on ventilation	6	567	−3.57 [−4.22, −2.91]	<0.0001	95%	−2.61 [6.29,1.07]	0.17	95%
Ventilator-free days	3	243	7.29 [6.88, 7.71]	<0.0001	96%	3.09 [−3.34, 9.51]	0.35	96%
LOS-ICU	8	656	−2.76 [−3.42, −2.10]	<0.0001	92%	−1.35 [−4.12, 1.43]	0.34	92%
LOS-H	4	217	−5.04 [−5.86, −4.22]	<0.0001	99%	−10.56 [−19.76, −1.36]	0.02	99%

LOS-H – length of stay in hospital, LOS-ICU – length of stay in intensive care unit, RR – relative risk, WMD – weighted mean difference.

ISSN: 1476-511X